Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial

Blood (2024) 144 (Supplement 1): 3158.

https://doi.org/10.1182/blood-2024-205465

Published: 2024

Journal Articles

Optimizing Molecular Diagnosis of Systemic Mastocytosis in the Era of KIT Tyrosine Kinase Inhibitors: Results of a Survey and of a Nationwide Proficiency Control Round of KIT D816V Mutation Testing Promoted By the RIMA (Rete Italiana MAstocitosi) Association

Blood (2024) 144 (Supplement 1): 7640.

https://doi.org/10.1182/blood-2024-202485

Published: 2024

Journal Articles

Loss of Function of SETD2 Tumor Suppressor in Chronic Myeloid Leukemia (CML) Progenitors Fosters Genomic Instability and Enhances Clonogenic Potential

Sara De Santis, Manuela Mancini, Cecilia Monaldi, Gabriele Gugliotta, Samantha Bruno, Fausto Castagnetti, Miriam Iezza, Marco Cerrano, Alessandra Iurlo, Sara Galimberti, Serena Balducci, Fabio Stagno, Michele Cavo, Simona Soverini

Blood (2023) 142 (Supplement 1): 1785.

https://doi.org/10.1182/blood-2023-185677

Published: 2023

Journal Articles

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Blood (2023) 142 (Supplement 1): 6393.

https://doi.org/10.1182/blood-2023-181521

Published: 2023

Journal Articles

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

Blood (2019) 134 (Supplement_1): 4142.

https://doi.org/10.1182/blood-2019-126500

Published: 2019

Journal Articles

In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors

Blood (2019) 134 (Supplement_1): 4204.

https://doi.org/10.1182/blood-2019-126538

Published: 2019

Journal Articles

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Induces Genetic Instability and Can be Therapeutically Targeted

Blood (2018) 132 (Supplement 1): 1726.

https://doi.org/10.1182/blood-2018-99-112908

Published: 2018

Journal Articles

MDM2 and Aurora Kinase a Contribute to SETD2 Loss of Function in Advanced Systemic Mastocytosis: Implications for Pathogenesis and Treatment

Blood (2018) 132 (Supplement 1): 1779.

https://doi.org/10.1182/blood-2018-99-113278

Published: 2018

Journal Articles

SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications

Blood (2017) 130 (Supplement 1): 2944.

https://doi.org/10.1182/blood.V130.Suppl_1.2944.2944

Published: 2017

Journal Articles

Targeting WEE1 Kinase after G2/M Checkpoint Arrest Induces Apoptosis in Chronic Myeloid Leukemia Progenitors

Manuela Mancini, PhD, Sara De Santis, Cecilia Monaldi, Fausto Castagnetti, MD PhD, Luana Bavaro, Margherita Martelli, Gabriele Gugliotta, MD PhD, Gianantonio Rosti, MD, Elena Tenti, PhD, Maria Alessandr Santucci, MD, Michele Cavo, MD, Giovanni Martinelli, MD, Simona Soverini, PhD

Blood (2017) 130 (Supplement 1): 1588.

https://doi.org/10.1182/blood.V130.Suppl_1.1588.1588

Published: 2017

Journal Articles

Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells

Manuela Mancini, PhD, Cecilia Monaldi, Sara De Santis, Cristina Papayannidis, MD, Michela Rondoni, MD, Maria Chiara Abbenante, MD, Luana Bavaro, Margherita Martelli, Roberta Zanotti, MD, Livio Pagano, MD, Michele Cavo, MD, Peter Valent, MD, Giovanni Martinelli, MD, Simona Soverini, PhD

Blood (2017) 130 (Supplement 1): 5290.

https://doi.org/10.1182/blood.V130.Suppl_1.5290.5290

Published: 2017

Journal Articles

SETD2 Loss of Function Is a Recurrent Event in Advanced-Phase Chronic Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 43.

https://doi.org/10.1182/blood.V130.Suppl_1.43.43

Published: 2017

Journal Articles

The Genomic and Transcriptomic Landscape of Systemic Mastocytosis

Blood (2016) 128 (22): 3136.

https://doi.org/10.1182/blood.V128.22.3136.3136

Published: 2016

Journal Articles

The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy

Simona Soverini, Caterina De Benedittis, Stefania Stella, Anna Serra, Francesca Carnuccio, Santa Errichiello, PhD, Luana Bavaro, Fausto Castagnetti, MD, Alessandra Iurlo, MD, Nicola Orofino, MD, Federica Sorà, Simona Sica, Sara Galimberti, MD PhD, Claudia Baratè, Federica Mottadelli, Margherita Martelli, Elisabetta Novella, Eros Di Bona, MD, Giorgina Specchia, Francesco Albano, Elisabetta Abruzzese, MD, Fabio Ciceri, MD, Francesca Lunghi, MD, Carmen Fava, MD, Giovanna Rege Cambrin, MD, Luigia Luciano, Massimo Breccia, MD, Clementina Caracciolo, MD, Marco Santoro, Francesco Di Raimondo, MD, Gabriele Gugliotta, Cristina Papayannidis, MD PhD, Giovanni Cazzaniga, Manuela Mancini, Rosaria Sancetta, Renato Bassan, Caterina Musolino, MD, Giuseppina Spinosa, Silvana Franca Capalbo, Mario Annunziata, MD, Michele Cavo, MD, Gianantonio Rosti, Michele Baccarani, Paolo Vigneri, Giuseppe Saglio, MD, Fabrizio Pane, Giovanni Martinelli

Blood (2016) 128 (22): 3097.

https://doi.org/10.1182/blood.V128.22.3097.3097

Published: 2016

Journal Articles

Clinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters

Simona Soverini, PhD, Caterina De Benedittis, PhD, Claudia Venturi, PhD, Cristina Papayannidis, MD PhD, Manuela Mancini, PhD, Katerina Machova Polakova, Domenico Russo, MD PhD, Paola Bresciani, MD, Alessandra Iurlo, MD PhD, Elisabetta Abruzzese, MD, Federica Sorà, MD PhD, Michele Baccarani, Michele Cavo, MD, Torsten Haferlach, Giovanni Martinelli, MD PhD

Blood (2015) 126 (23): 2489.

https://doi.org/10.1182/blood.V126.23.2489.2489

Published: 2015

Journal Articles

BCR-ABL Mutations in Chronic Myeloid Leukemia (CML) Patients (pts) with Failure and Warning to First- and Second-Line Tyrosine Kinase Inhibitor (TKI) Therapy: What Is the Advantage of Next-Generation Sequencing (NGS) over Conventional Sequencing?

Blood (2015) 126 (23): 346.

https://doi.org/10.1182/blood.V126.23.346.346

Published: 2015

Journal Articles

Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis

Blood (2015) 126 (23): 4085.

https://doi.org/10.1182/blood.V126.23.4085.4085

Published: 2015

Journal Articles

Aurora Kinase a: A New Component of Imatinib Resistance in Chronic Myeloid Leukemia

Manuela Mancini, PhD, Simona Soverini, Elisa Leo, PhD, Fausto Castagnetti, PhD, Caterina De Benedittis, PhD, Gabriele Gugliotta, PhD, Gianantonio Rosti, MD, Maria Alessandra Santucci, MD, Michele Cavo, Giovanni Martinelli, MD PhD

Blood (2015) 126 (23): 1573.

https://doi.org/10.1182/blood.V126.23.1573.1573

Published: 2015

Journal Articles

FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia

Elisa Leo, PhD, Giorgia Simonetti, PhD, Manuela Mancini, PhD, Nevena Veljkovic, PhD, Virginia Campi, Fausto Castagnetti, MD, Gabriele Gugliotta, MD, Caterina De Benedittis, Maria Alessandra Santucci, MD, Giovanni Martinelli, MD

Blood (2014) 124 (21): 3125.

https://doi.org/10.1182/blood.V124.21.3125.3125

Published: 2014

Journal Articles

Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia

Blood (2014) 124 (21): 1881.

https://doi.org/10.1182/blood.V124.21.1881.1881

Published: 2014

NARROW

Optimizing Molecular Diagnosis of Systemic Mastocytosis in the Era of KIT Tyrosine Kinase Inhibitors: Results of a Survey and of a Nationwide Proficiency Control Round of KIT D816V Mutation Testing Promoted By the RIMA (Rete Italiana MAstocitosi) Association

Loss of Function of SETD2 Tumor Suppressor in Chronic Myeloid Leukemia (CML) Progenitors Fosters Genomic Instability and Enhances Clonogenic Potential

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Induces Genetic Instability and Can be Therapeutically Targeted

MDM2 and Aurora Kinase a Contribute to SETD2 Loss of Function in Advanced Systemic Mastocytosis: Implications for Pathogenesis and Treatment

SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications

Targeting WEE1 Kinase after G2/M Checkpoint Arrest Induces Apoptosis in Chronic Myeloid Leukemia Progenitors

Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells

SETD2 Loss of Function Is a Recurrent Event in Advanced-Phase Chronic Myeloid Leukemia

The Genomic and Transcriptomic Landscape of Systemic Mastocytosis

The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy

Clinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters

BCR-ABL Mutations in Chronic Myeloid Leukemia (CML) Patients (pts) with Failure and Warning to First- and Second-Line Tyrosine Kinase Inhibitor (TKI) Therapy: What Is the Advantage of Next-Generation Sequencing (NGS) over Conventional Sequencing?

Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis

Aurora Kinase a: A New Component of Imatinib Resistance in Chronic Myeloid Leukemia

FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia

Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only